Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection

Sodium glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RA) were initially approved to improve glycemic control in the treatment of type 2 diabetes. Clinical trials have also demonstrated beneficial effects with regards to cardiovascular and renal parame...

Descripción completa

Detalles Bibliográficos
Autores principales: Sridhar, Vikas S., Dubrofsky, Lisa, Boulet, Jacinthe, Cherney, David Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Nefrologia 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7860654/
https://www.ncbi.nlm.nih.gov/pubmed/32926067
http://dx.doi.org/10.1590/2175-8239-JBN-2020-0100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7860654/
https://www.ncbi.nlm.nih.gov/pubmed/32926067
http://dx.doi.org/10.1590/2175-8239-JBN-2020-0100

Ejemplares similares